3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
13
OTHER_GOV
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
241
Carboplatin
170
Injections
139
Paclitaxel
122
Gemcitabine
118
Bevacizumab
117
Cisplatin
108
Pemetrexed
80
Docetaxel
80
Cyclophosphamide
74
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
60
Nivolumab
55
Cetuximab
53
fludarabine
52
Leucovorin
51
130-nm albumin-bound paclitaxel
50
Dexamethasone
46
Rituximab
41
atezolizumab
38
venetoclax
35
toripalimab
35
Drug Therapy
35
enzalutamide
32
Prednisone
32
Letrozole
32
Irinotecan
32
durvalumab
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Transurethral Resection of Prostate
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled